Anaprazole Sodium

安奈拉唑钠

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameAnaprazole Sodium
Drug Alias Name安纳拉唑钠Anaprozole Sodium安久卫KBP-3571
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium-transporting ATPase inhibitors
TargetsPotassium-transporting ATPase
Therapy Area/IndicationsHelicobacter pylori infectionStomach UlcerDuodenal Ulcer +[10] 
Global Approved IndicationsDuodenal Ulcer
Approved Indications in ChinaDuodenal Ulcer
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXuanzhu (Beijing) Pharm Co LtdXuanzhu (HK) Biopharmaceutical Ltd
Inactive CompaniesShandong Xuanzhu Pharmaceutical Technology Co LtdSihuan Pharmaceutical Holdings Group LtdBeijing Sihuan Pharmaceutical Co Ltd +[4] 
Active IndicationsHelicobacter pylori infectionDuodenal UlcerEsophagitis, Peptic +[9] 
Inactive IndicationsStomach Ulcer

Other Information

ATC CodeN/A
Related LinksN/A